Lexeo Therapeutics (LXEO) Change in Accured Expenses (2022 - 2026)

Lexeo Therapeutics (LXEO) has 5 years of Change in Accured Expenses data on file, last reported at -$1.1 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 147.17% year-over-year to -$1.1 million; the trailing twelve-month figure through Mar 2026 stood at -$7.9 million (down 536.95% YoY), and the FY2025 full-year result was -$4.4 million, down 232.02% from the prior year.
• Change in Accured Expenses eased to -$1.1 million in Q1 2026, from -$619000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $5.3 million in Q3 2024 to a low of -$7.1 million in Q2 2025.
• A 5-year average of -$70500.0 and a median of -$763500.0 in 2022 frame the typical range for Change in Accured Expenses.
• Peak annual rise in Change in Accured Expenses reached 317.16% in 2024, while the deepest fall reached 421.63% in 2024.
• Tracing LXEO's Change in Accured Expenses over 5 years: stood at -$908000.0 in 2022, then slumped by 133.48% to -$2.1 million in 2023, then advanced by 9.34% to -$1.9 million in 2024, then soared by 67.79% to -$619000.0 in 2025, then tumbled by 76.41% to -$1.1 million in 2026.
• Business Quant data shows LXEO's Change in Accured Expenses at -$1.1 million in Q1 2026, -$619000.0 in Q4 2025, and $996000.0 in Q3 2025.